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Multiple myeloma remains an incurable and ultimately fatal plasma cell neoplasm de-spite significant progress in the under-
standing of myeloma pathogenesis and incorporation 
of newer agents in the treatment armamentarium.1-9 
High-dose chemotherapy followed by autologous he-
matopoietic cell transplantation (auto-HCT), with or 
without novel agents, remains the standard of care for 
newly diagnosed patients with multiple myeloma who 
are deemed candidates for such therapy.10-14 Although 
treatment outcomes have improved, patients are at a 
continuous risk of disease progression and relapse af-
ter auto-HCT and only a minority of patients achieve 
long-term disease-free survival (DFS) of 10 years or 
more.12,13 Allogeneic HCT (allo-HCT) from a human 
leukocyte antigen (HLA)-matched sibling (MRD) or 
an unrelated donor (URD) is another treatment option 
Role of reduced intensity conditioning in 
allogeneic hematopoietic cell transplantation 
for patients with multiple myeloma
Taiga Nishihori,a Mohamed A. KharfancDabaja,b Jose L. OchoacBayona,a Ali Bazarbachi,b Marcelo 
Pasquini,c Melissa Alsinaa
from the aDepartment of Blood and marrow transplantation, h. Lee moffitt Cancer Center and research institute, university of south florida, 
tampa, florida, usa, bDepartment of internal medicine, Division of hematology-oncology-Bmt and naef K. Basile Cancer institute, american 
university of Beirut, Beirut, Lebanon, and the cmedical College of Wisconsin, milwaukee, Wisconsin, usa.
Correspondence: taiga nishihori, mD · Department of Blood and marrow transplantation, h. Lee moffitt Cancer Center and research institute, 
university of south florida, tampa, florida, usa · taiga.nishihori@moffitt.org · accepted: march 2011
hematol oncol stem Cel ther 2011; 4(1): 1-9
Doi: 10.5144/1658-3876.2011.1
high-dose chemotherapy followed by autologous hematopoietic cell transplantation continues to play an 
integral role in the treatment strategy in patients with newly diagnosed multiple myeloma. incorporation 
of newer potent anti-myeloma agents has further improved outcomes. however, disease relapse or pro-
gression remains a challenge after autologous transplantation. allogeneic hematopoietic cell transplanta-
tion remains the only potentially curative modality for some patients due in part to graft-versus-myeloma 
effect. high transplant-related mortality, in the range of 30% to 40%, previously seen with myeloablative 
conditioning regimens including total body irradiation plus cyclophosphamide has been significantly 
reduced by introducing less ablative preparative regimens, so called reduced-intensity conditioning. 
Cumulative evidence suggests encouraging prospects for allogeneic transplantation through improved 
outcomes of myeloma patients (overall survival exceeding 70% at 2 years in some studies); however, 
which patient population would benefit most from this treatment remains to be defined. newer strategies 
to augment graft-versus-myeloma effect and minimize post transplant toxicities are in need of further 
improvement in patients with myeloma. 
in myeloma. Advantages of an allo-HCT include use 
of a tumor-free graft and immune-mediated effect of 
graft-versus-myeloma.15 
Despite the curative potential of allo-HCT, trans-
plant-related mortality (TRM) is a major challenge and 
thus not all patients are deemed eligible for this treatment 
approach. Allo-HCT with myeloablative conditioning is 
traditionally limited to younger patients with good per-
formance status or who are refractory to conventional 
chemotherapy primarily due to the high TRM and mor-
bidity associated with the intense myeloablative condi-
tioning regimens utilized in the past.16-18 After 2000, the 
indications for an allo-HCT have been dramatically ex-
panded following the introduction of reduced-intensity 
or non-myeloablative conditioning regimens.19 These 
regimens broadened eligibility of allo-HCT to ages up 
to 70 years, even in patients with comorbid conditions. 
review reduCed inTenSiTy COndiTiOning in mm
Hematol Oncol Stem Cell Ther 4(1)     First Quarter 2011 hemoncstem.edmgr.com2
In these newer strategies, auto-HCT was sequenced 
with allo-HCT to first debulk myeloma and then to 
subsequently eradicate tumor by alloreactive donor T 
cells.20,21 Here, we review the current literature on the 
use of reduced-intensity conditioning (RIC) regimens 
and graft-versus-myeloma effect.
Historical perspectives on myeloablative cond
ditioning
Traditional myeloablative regimens have included cy-
clophosphamide with total body irradiation (TBI), 
cyclophosphamide plus busulfan, or melphalan plus 
TBI.16-18,22 These regimens are less commonly used in 
recent years due to an unacceptably high TRM of up 
to 60%.16-18 Reasons for high TRM in myeloma pa-
tients are in large part unclear; however, underlying 
organ dysfunctions and/or immunodeficiency associ-
ated with myeloma are speculated to be factors asso-
ciated with increased mortality risk. In a large single 
center experience from Seattle, 136 heavily pretreated 
patients younger than 60 years received hematopoietic 
cell allografts, between 1987 to 1999, from either a 
MRD (84%) or URD (16%).17 TRM at day 100 after 
transplant was 48%. Overall survival (OS) at 5 years 
was only 22% with DFS of only 14%. In patients who 
achieved complete remission (CR) after transplant, 
OS and DFS at 5 years were 48% and 37%, respec-
tively. Furthermore, TRM was approximately 20% for 
patients who had chemosensitive disease at the time 
of transplant and were within one year from the time 
of diagnosis.
The US Intergroup Trial S9321 that included a my-
eloablative allo-HCT arm for patients younger than 55 
years with an HLA-identical sibling donor showed a 
high TRM of 53% which led to early discontinuation 
of this arm.23 Of note, 22% of patients enrolled were 
still alive and progression-free even 7 years after trans-
plant. The OS and event-free survival curves reached a 
plateau at 10 years indicating a probability of achieving 
a “cure” in a subgroup of patients. Despite a significantly 
high TRM with myeloablative allo-HCT, it is widely 
believed that better clinical outcomes are achieved in a 
subset of chemosensitive myeloma patients. Molecular 
remissions are shown to be more frequent after my-
eloablative allogeneic HCT than auto HCT despite 
the similar conditioning intensity.24 Recently, long-term 
encouraging results of a small study using intensified 
myeloablative conditioning with TBI, busulfan, cyclo-
phosphamide and anti-thymocyte globulin (ATG) have 
been reported.25 Thus, for certain groups of advanced 
myeloma patients, myeloablative regimens could be 
considered in clinical trials. 
Reduceddintensity conditionings
Although there has been prohibitive TRM with mye-
loablative allo-HCT, evidence from long-term survivors 
have suggested some benefit of graft-versus-myeloma 
in disease control. These observations led investigators 
to further explore highly immunosuppressive, but less 
toxic, conditionings that could safely facilitate engraft-
ment while reducing TRM.26 These conditionings were 
termed reduced-intensity and non-myeloablative regi-
mens depending on the intensity of the dose or com-
bination of agents. The most widely accepted regimen 
was originally developed in Seattle where preclinical 
animal studies demonstrated stable donor cell engraft-
ment after a truly non-myeloablative regimen consisted 
of low-dose TBI (200 cGy) followed by immunosup-
pression with cyclosporine and mycophenolate mofetil 
(MMF).27 This platform was soon translated to clinical 
application with addition of fludarabine to reduce the 
rate of graft rejection.28 
The European Group for Blood and Marrow 
Transplantation (EBMT) reported its retrospective 
registry data comparing myeloablative and non-my-
eloablative conditioning.29 In this study, TRM was sig-
nificantly reduced with RIC regimens, but because of 
higher relapse and progression rates there was no sig-
nificant improvement in OS. The study was also limited 
due to significant differences in prognostic variables and 
treatment modalities between the two groups. The rep-
resentative RIC regimens are summarized in Table 1. 
Prospective trials of autodallo HCT approach
A novel treatment modality was designed for patients 
with newly diagnosed multiple myeloma where an ini-
tial auto-HCT was followed by a low-dose TBI-based 
nonmyeloablative allograft.21 The rationale for the “tan-
dem auto-allo HCT” approach was to separate in time 
(a) cytoreduction with standard high-dose melphalan 
at 200 mg/m2 and (b) the graft-versus-myeloma effect 
with the potential of dramatically reducing the TRM. 
The initial multicenter prospective trial by the Seattle 
Consortium enrolled 54 newly diagnosed myeloma 
patients, median age of 52 years, with stage II-III with 
half of them having refractory or relapsed disease.21 
Fifty-two of 54 patients completed the assigned treat-
ment. They reported a CR rate of 57% and TRM of 
22%. After a median follow-up of 60 months, OS and 
progression-free survival (PFS) were 69% and 38%, re-
spectively. The long-term outcomes using the same ap-
proach after 6.3 years of follow-up was reported, even 
though the tandem auto-allo HCT was not used in 
the first-line setting in all patients.30 Grade II-IV acute 
GVHD occurred in 42% of cases and 74% experienced 
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chronic GVHD. TRM at 5 years was 18%, primarily 
due to GVHD and/or infections. The overall response 
rate (ORR) was 94% (CR=65%, PR=29%). Median 
OS was not reached and PFS was 3 years (Table 2). 
The Gruppo Italiano Trapianti di Midollo Osseo 
(GITMO) reported their experience with the same 
tandem auto-allo HCT approach.31 A prospective mul-
ticenter study enrolled 100 newly diagnosed younger 
patients (age < 65 years). With a median follow-up of 
5 years, OS was not reached and EFS was 37 months 
(Table 2). Acute and chronic GVHD occurred in 38% 
and 50% of patients, respectively. CR was achieved 
in 53% of patients. CR or very good partial response 
(VGPR) prior to allografting was significantly associ-
ated with achievement of post-transplant remission 
and longer EFS. Several other groups have employed 
reduced-intensity regimens in clinical trials including 
melphalan 100-140 mg/m2 with or without fludara-
bine, 200 cGy TBI with or without fludarabine, and 
intermediate-dose busulfan. Anti-thymocyte globulin 
(ATG) or alemtuzumab have been also used for in vivo 
T cell depletion for the purpose of reducing the inci-
dence of GVHD.32-39 
Comparison of autodauto (tandem auto) versus 
autodallo HCT approach
The platform of tandem auto-allo HCT was compared 
to a tandem auto-auto approach in several studies 
(Table 3). The Intergroupe Francophone du Myélome 
(IFM) treated 284 newly diagnosed myeloma patients 
with high-risk features (elevated beta-2-microglobu-
lin and chromosome 13 deletion) on two protocols 
(IFM99-03 and IFM99-04).40 All patients received 
VAD induction followed by a first autograft with high-
dose melphalan at 200 mg/m2. Sixty-five patients with 
MRD subsequently received an allograft with busul-
fan, fludarabine and high-dose ATG 12.5 mg/kg con-
ditioning (IFM99-03). This arm was compared with 
219 patients who underwent a second autograft after 
high-dose melphalan at 220 mg/m2 (IFM99-04) given 
the proven benefit of tandem auto-HCT by IFE 13 and 
suboptimal disease control with single auto-HCT in 
high-risk patients.41 TRM and response rates were sim-
ilar. At a median follow-up of 2 years, OS and EFS were 
35% and 25% in auto-allo cohort, and 41% and 30% 
in tandem auto cohort, respectively (Table 3). These 
findings may suggest that patients with high-risk fea-
tures did not benefit from a RIC allogeneic HCT. It is 
possible that, administration of high-dose ATG might 
have hindered, to some extent, the potentially curative 
graft-versus-myeloma effects as the incidence of chronic 
GVHD was only 7%. The examination of the impact of 
myeloma genetic abnormalities on allo-HCT outcomes 
warrants further comprehensive analyses.
The Italian group enrolled 162 consecutive young-
er (age ≤65) patients with newly diagnosed myeloma 
who had at least one sibling.42 Elevated beta-2-micro-
globulin level (≥3.5 mg/L) and chromosome 13 dele-
tions were seen in 35% (n=143) and 40% (n=52) of 
patients, respectively. All patients received a vincristine, 
doxorubicin, and dexamethasone (VAD)-based induc-
tion regimen followed by an autograft with melphalan. 
Eighty patients with HLA-matched sibling donor were 
offered TBI-based nonmyeloablative regimen followed 
by granulocyte colony-stimulating factor (G-CSF)-mo-
bilized peripheral blood allografting, whereas 82 pa-
tients without an HLA-identical sibling were assigned 
to receive a second autograft after high-dose (140-200 
mg/m2) or intermediate-dose (100 mg/m2) melphalan. 
One hundred and four patients completed the assigned 
treatment plan. At a median follow-up of 45 months, 
OS and EFS were 80 vs. 54 months and 35 vs. 29 
months (auto-allo versus tandem auto), respectively. 
Having an HLA-matched donor was associated with 
longer OS and EFS in multivariate analysis. CR rates 
were 55% versus 26%, respectively. TRM were 10% 
and 2%, respectively. Median OS was not reached in 
the auto-allo cohort and was 58 months in the tandem 
auto arm. EFS were 43 and 33 months, respectively.42 
Table 1. representative reduced-intensity conditioning (riC) 
regimens for multiple myeloma.
Conditioning regimen References
Fludarabine + TBI
  Fludarabine: 0 mg/m2 ×  days
0, 42, 21
  TBi: 200 cgy (7 cgy/min)
Fludarabine + melphalan ± ATG
  Fludarabine: 0 mg/m2 ×  days
69  melphalan: 70 mg/m2 × 2 days
  rabbit ATg (Fresenius): 0 mg/m2 ×  days
Fludarabine + cyclophosphamide
  Fludarabine: 0 mg/m2 × 5 days
70
  Cyclophosphamide: 1000 mg/m2 × 2 days
Busulfan + fludarabine + ATG
  Busulfan: 2 mg/kg × 2 days
40  Fludarabine: 25 mg/m2 × 5 days
  ATg (imtix genzyme): 2.5 mg/kg × 5 days
Abbreviations: ATg, anti-thymocyte globulin; cgy, centigray; TBi, total body irradiation
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In a multivariate analysis classifying patients with either 
high beta-2-microglobulin or a chromosome 13 abnor-
mality (i.e., high-risk group), the adjusted hazard ratios 
were 0.34 (95% confidence interval (CI), 0.10 to 1.18) 
for OS and 0.52 (95% CI, 0.22 to 1.21) for EFS; these 
results were similar to those noted for all 162 patients 
combined. 
Another biologic randomization study has been 
reported by the Spanish (PETHEMA) group.43 One-
hundred ten patients with newly diagnosed myeloma 
who failed to achieve at least near CR after a first auto-
HCT were treated with either a second auto-HCT 
(n=85) or a RIC with fludarabine and melphalan fol-
lowed by allografting (n=25) depending on the HLA-
matched sibling donor availability. CR rate was higher 
(40% versus 11%; P=.001) in the auto-allo arm. There 
was a trend towards a longer PFS (median, 31 months 
versus not reached; P=.08) in the reduced intensity 
group, which is in line with the result reported by the 
Italian group showing a lower relapse rate after auto-
Table 2. Selected published prospective phase ii trials of auto-allo approach in newly diagnosed myeloma patients.
Study  
reference No. Donor
Regimen
GVHD 
prophylaxis
%
Auto Allo AGVHD II-IV CGVHD TRM CR rate
OS at 5 
years
Bruno1 100 mrd meL 200
TBi 200 
cgy CSA+mmF 8 50 11 5 65
rotta0 102 mrd
meL 
200
meL 
140 
(n=2)
BeAm 
(n=1)
TBi 200 
cgy
TBi 200 
cgy + Flu 
0 mg/m2 
(n=27)
CSA+mmF
TAC+mmF 42 74 18 62 64
Abbreviations: AgVHd, acute graft-versus-host disease; Allo, allogeneic; Auto, autologous; BeAm, BCnu, etoposide, cytarabine and melphalan; CgVHd, chronic graft-versus-host 
disease; cgy, centigray; Cr, complete response; CSA, cyclosporine; Flu, fludarabine; meL 140, melphalan at 140 mg/m2; meL 200, melphalan at 200 mg/m2; mmF, mycophenolate 
mofetil; mrd, matched-related donor; OS, overall survival; TAC, tacrolimus; TBi, total body irradiation; Trm, transplant-related mortality
Table 3. Selected Studies Comparing Auto-Allo versus Tandem Auto Approaches
Study 
reference No. Regimen
GVHD 
prophylaxis
%
AGVHD 
II-IV CGVHD TRM CR rate
OS
(years)
Bruno42   
80 meL 200 → meL 200 n/A n/A n/A 4 26 5 (4)
82 meL 200 → TBi 200 cgy CSA+mmF 4 2 10 55 75 (4)
garban40/
moreau71
219 meL 200  → meL 220 n/A n/A n/A 5  44 (5)
65 meL 200 → Bu Flu ATg CSA+mTX 24 4 11   (5)
rosiñol4
88 meL 200 → meL 200 or CBV n/A n/A n/A 5 11 60 (5)
26 meL 200 → Flu meL 140 CSA+mTX 2 66 16  62 (5)
Knop72
7 meL 200 → meL 200 n/A n/A n/A nr 2 70 ()
126 meL 200  → Flu meL 140 ± ATg nr nr nr 16 59 60 ()
Lokhorst7
141 meL 200 → maintenance n/A n/A n/A nr 42 56 (4)
126 meL 200  → TBi 200 cgy nr nr nr 14 45 6 (4)
gahrton46
251 meL 200  → meL 200 n/A n/A n/A nr 8 57 (5)
107 meL 200  → Flu TBi 200 cgy nr nr nr 1 4 60 (5)
Abbreviations: AgVHd, acute graft-versus-host disease; Allo, allogeneic; ATg, antithymocyte globulin; Auto, autologous; Bu, busulfan; CgVHd, chronic graft-versus-host disease; 
cgy, centigray; Cr, complete response; CSA, cyclosporine; Flu, fludarabine; meL 140, melphalan at 140 mg/m2; meL 200, melphalan at 200 mg/m2; meL 220, melphalan at 220 
mg/m2; mmF, mycophenolate mofetil; mTX, methotrexate; n/A, not applicable; nr, not reported; OS, overall survival; TAC, tacrolimus; TBi, total body irradiation; Trm, transplant-
related mortality
reviewreduCed inTenSiTy COndiTiOning in mm
Hematol Oncol Stem Cell Ther 4(1)     First Quarter 2011 hemoncstem.edmgr.com 5
allo HCT than tandem auto-HCT. However, TRM 
appears to be higher (16% versus 5%; P=.07) in the 
auto-allo HCT patients. There were no statistically 
significant differences in OS and EFS (Table 3), which 
may be due in part to smaller number of patients treat-
ed in auto-allo HCT arm.
Most recently, the Blood and Marrow Transplant 
Clinical Trials Network (BMT CTN) reported a multi-
center phase III trial (BMT CTN 0102) where patients 
were biologically assigned based on availability of HLA-
matched sibling donor to either tandem auto arm using 
melphalan 200 mg/m2 or an auto-allo approach using 
melphalan 200 mg/m2 followed by allogeneic HCT 
with 200 cGy TBI.44, 45 GVHD prophylaxis consisted 
of cyclosporine and MMF. The primary endpoint of the 
study was 3-year PFS in patients with standard risk dis-
ease (absence of chromosome 13 deletion by metaphase 
karyotype and 2-microglobulin <4 mg/L). There were 
710 patients enrolled at 37 US centers between 2003 
and 2007. Among them, 625 patients were standard 
risk. Patients assigned to tandem auto-HCT arm were 
further randomized to maintenance of thalidomide plus 
dexamethasone for 1 year post-transplant or observa-
tion. Compliance with maintenance was low, and PFS 
and OS were no different between maintenance and 
observation, hence these two tandem auto-HCT arms 
were combined for the comparison with auto-allo HCT 
arm. Patients in the tandem auto-HCT (n=189) arms 
were older (median age 55 vs. 52 years; P=.01). Three-
year PFS was 46% vs. 43% (P=.67), and 3-year OS was 
80% vs. 77% (P=.19) for the tandem auto-HCT and 
auto-allo-HCT groups, respectively. Three-year TRM 
were 4% and 11% (P=.04). Among the auto-allo HCT 
patients, probabilities of grade III-IV acute and chronic 
GVHD were 9% and 47%, respectively. Eighty-two per-
cent of patients in each arm received the assigned second 
transplant. The study did not show added benefit of the 
auto-allo HCT approach over tandem auto-HCT at 3 
years.44,45 Other studies in myeloma demonstrated that 
differences in survival may appear beyond 5 years, thus 
further follow-up will be important to assess the true 
benefit of the auto-allo HCT approach.46 
Evidence of graftdversusdmyeloma effects and 
roles of donor lymphocyte infusions
The potentially curative effect of an allo-HCT relies on 
the immunologic mechanism by which donor-derived al-
loreactive T cells target myeloma-specific antigens, hence 
producing graft-versus-myeloma effects. Direct evidence 
for the existence of such effects comes from the transfer 
of myeloma idiotype-specific immunity from an immu-
nized marrow donor to the patient.47 Indirect proof of 
the principle was documented by the achievement of CR 
following the infusion of donor-derived lymphocytes or 
discontinuation of immunosuppression and consequent 
development of GVHD in patients who relapsed after 
an allo-HCT.48-51 Although donor lymphocyte infu-
sions (DLI) have been showed to induce high response 
rates in large studies, durable remissions could only be 
achieved in a small number of patients. Evidence also 
suggests the presence of graft-versus-myeloma effect 
based on the fact that the molecular remissions are more 
commonly observed with allo-HCT using myeloabla-
tive conditioning compared to auto-HCT.24 The major 
morbidities of DLI were acute and chronic GVHD 
which were reported in up to 55% and 26% of patients, 
respectively.51 Some studies reported that the strongest 
predictors for response to DLI were the occurrence of 
acute and chronic GVHD,52-54 suggesting that GVHD 
and the graft-versus-myeloma effect could potentially 
share the same antigenic targets (i.e., minor histocom-
patibility antigens (mHA) expressed both on recipients 
normal and myeloma cells). Susceptibility of malignant 
plasma cells to a mHA, HA-1, specific lysis in vitro sug-
gests a role for the HA-1 in the graft-versus-myeloma 
effect.55 In a patient with myeloma who received an 
HLA-matched, mHA mismatched DLI, achievement of 
CR was accompanied by the emergence and expansion 
of HA-1, HA-2, and LB-ATP-dependent interferon-
responsive (ADIR)-1F-specific cytotoxic T cells in the 
circulation.56 
Historically, chronic GVHD has been associated 
with decreased relapse and better OS in several my-
eloid malignancies after allo-HCT.57 A Center for 
International Bone Marrow and Transplant Research 
(CIBMTR) analysis showed that the protective effect 
of chronic GVHD on myeloma relapse in patients who 
were treated with reduced intensity or non-myeloabla-
tive regimens.58 However, in a study by the GITMO, 
the development of chronic GVHD did not correlate 
with the achievement of remission or durability of re-
sponse.31 Additionally, responses to DLI may occur 
without GVHD, indicating that tumor-associated anti-
gens could also be involved, as illustrated by strong anti-
body responses against cancer testis antigen and MUC-
1.59,60 Kröger, et al used DLI to treat patients who only 
achieved partial remission (PR) after allogeneic HCT.61 
Addition of novel agents after DLI also upgraded the 
response to CR. There was no clear association with 
the development of GVHD and response to DLI. The 
relation between graft-versus-myeloma and GVHD af-
ter RIC allo-HCT appears to be less clear. It is possible 
that a graft-versus-myeloma effect may be distinct from 
chronic, clinically overt, GVHD and associated with 
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subclinical GVHD after RIC allo-HCT transplants. 
These observations suggest that more detailed exami-
nations are required to explore the exact mechanisms 
of graft-versus-myeloma effects which could result in 
newer strategies to investigate T-cell therapy focusing 
on mHA differences. 
Use of novel targeted agents before and after 
allogeneic transplantation
Novel anti-myeloma agents with immunomodulating 
capabilities including bortezomib could also be of poten-
tial therapeutic interest when considering an allo-HCT 
approach. In preclinical studies, bortezomib prevented 
GHVD while the graft-versus-myeloma effects were 
preserved.62,63 In a clinical study, bortezomib combined 
with tacrolimus and methotrexate as GVHD prophy-
laxis proved to be effective regimen after RIC allo-HCT 
in mismatched unrelated donors.64 When bortezomib 
was used after RIC allo-HCT, 27 of 37 (73%) patients 
had an objective response without worsening GVHD.65 
Despite these successful applications, bortezomib has 
not been routinely advocated post allo-HCT primar-
ily due to potentially concerning side effects. Both tha-
lidomide and lenalidomide have been used following 
allo-HCT and have demonstrated favorable anti-my-
eloma effects.66,67 Lenalidomide may have less effect on 
GVHD and may even improve GVHD.67 It is plausible 
that lenalidomide could be particularly valuable option 
for relapsed patients post allo-HCT. Further research 
combining novel anti-myeloma agents in reduced inten-
sity HCT strategy to maximize graft-versus-myeloma 
effects is warranted. 
Conclusions
In summary, the prognosis of patients with myeloma 
has significantly improved over the last decade.  The 
current clinical experience suggests that allo-HCT 
may be effective treatment in a group of younger mul-
tiple myeloma patients with standard risk disease. The 
BMT CTN 0102 trial showed the outcomes in these 
patients are no different than a tandem auto-HCT ap-
proach at least at 3 years. The benefit of this approach 
in high-risk myeloma patients is still unknown. A 
recent consensus statement by the International 
Myeloma Working Group on allo-HCT concluded 
that convincing evidence is still lacking to definitively 
demonstrate superiority of an auto-allo HCT ap-
proach over tandem auto-HCT although introduc-
tion of RIC regimens has lowered the TRM.68 Based 
on the current literature on allo-HCT, the optimal 
methodology to exploit the maximal benefit of graft-
versus-myeloma effects needs to be further studied. 
The BMT CTN 0102 demonstrated an improvement 
in TRM compared to studies using myeloablative regi-
mens, however, benefits with graft-versus-myeloma ef-
fect were still offset by TRM. Further improvements 
in TRM to make transplants safer would maximize 
the benefits of an immune-mediated effect against my-
eloma. Research efforts should be directed to incor-
porate more novel anti-myeloma therapies and immu-
nologic approaches to further augment graft-versus-
myeloma effects. Furthermore, stratification of my-
eloma patients based on prognostic factors, especially 
chromosomal abnormalities, is essential to discern the 
patients who would benefit most from an allo-HCT 
procedure. Emerging advanced technologies including 
gene-expression profiling may help predicting biologic 
behavior of the disease and bone marrow microenvi-
ronment and help determine the factors influencing 
graft-versus-myeloma effects.
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